Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
An article from
Dive Brief
//
IPO window
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3…
Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might…
Palantir's government business along with developments in artificial intelligence have helped push the company's market value…
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Amplia takes aim at billion-dollar pancreatic cancer drug market
LifeSci Capital Remains a Buy on Ibio (IBIO)
Cerebras just had the biggest US tech IPO since Snowflake. SpaceX, OpenAI, and Anthropic are next.
Fintech firm Paramotor Digital files confidential IPO papers with SEBI
